ResMed, Inc.

The reinvention of Baxter goes on. The company that in the early 2000s was a permanent fixture among the global top 10 medtechs, focused on peritoneal and hemodialysis, will transform further in 2025

The reinvention of Baxter goes on. The company that in the early “noughties” was a permanent fixture among the global top 10 medtechs, focused on peritoneal and hemodialysis, will transform further in

Eli Lilly and Company ’s incretin drug tirzepatide is playing catch-up to Novo Nordisk A/S ’s semaglutide in many disorders. In obese patients with obstructive sleep apnea, however, it is ahead of th

ResMed, Inc. said it will lay off 5% of its global workforce and restructure parts of its business. This comes as the sleep device maker continues to benefit from competitor Philips Healthcare's si